Top Markets
Coin of the day
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT
Classifica tra le azioni #15062
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the... EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Prezzo delle azioni
$4.48
Ultima sincronizzazione: 2026-08-31
Capitalizzazione di mercato
$375.37M
Variazione (1 giorno)
-0.06%
Variazione (1 anno)
-61.30%
Paese
US
Scambia EyePoint Pharmaceuticals, Inc. (EYPT)

Categoria

Il prezzo EYPT con la capitalizzazione del mercato della B
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.
EYPT
$4.48
Capitalizzazione di mercato di EyePoint Pharmaceuticals, Inc.(EYPT)
Capitalizzazione di mercato: $375.37M
A partire dal September 2026, EyePoint Pharmaceuticals, Inc. ha una capitalizzazione di mercato pari a $375.37M. Questo rende EyePoint Pharmaceuticals, Inc. la 15062nd azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di EyePoint Pharmaceuticals, Inc. dal 2005 al 2026
EYPT in paragone con la classifica dei più popolari stocks
Il prezzo per EYPT Attivo B Capitalizzazione del mercato a B Risultati
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.
$63,534.36 $375.37M
$5.327T +1,418,964.69%
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.
$55,400.82 $375.37M
$4.645T +1,237,298.75%
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.
$48,547.20 $375.37M
$4.070T +1,084,220.59%
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.
$45,139.81 $375.37M
$3.785T +1,008,115.17%
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.
$33,278.62 $375.37M
$2.790T +743,190.94%